Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
Authors
Keywords
-
Journal
CNS Neuroscience & Therapeutics
Volume 28, Issue 7, Pages 981-991
Publisher
Wiley
Online
2022-04-15
DOI
10.1111/cns.13836
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
- (2021) Jan Traub et al. Pharmaceuticals
- What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)
- (2021) Edgar Carnero Contentti et al. Multiple Sclerosis and Related Disorders
- A Pilot Trial of Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optic Spectrum Disorder
- (2021) Jodie M. Burton et al. Multiple Sclerosis and Related Disorders
- Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges
- (2021) Caiyun Liu et al. AUTOIMMUNITY REVIEWS
- BLK polymorphisms and expression level in neuromyelitis optica spectrum disorder
- (2021) Bo‐Wen Yin et al. CNS Neuroscience & Therapeutics
- Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis
- (2020) Pengcheng Zhang et al. BONE MARROW TRANSPLANTATION
- Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder
- (2020) S.‐H. Kim et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
- (2020) Anthony Traboulsee et al. LANCET NEUROLOGY
- Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
- (2020) Chao Zhang et al. LANCET NEUROLOGY
- Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
- (2020) Masayuki Tahara et al. LANCET NEUROLOGY
- Evaluation of efficacy and tolerability of first-line therapies in NMOSD
- (2020) Julien Poupart et al. NEUROLOGY
- Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
- (2020) Giulia Ceglie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
- (2020) Jan Traub et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica
- (2020) Agnieshka M. Agasing et al. Nature Communications
- Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity
- (2020) Meng-Ge Yang et al. Multiple Sclerosis and Related Disorders
- Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
- (2020) Jyh Yung Hor et al. Frontiers in Neurology
- Update on neuromyelitis optica spectrum disorder
- (2020) Kathryn B. Holroyd et al. CURRENT OPINION IN OPHTHALMOLOGY
- Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder
- (2020) Trygve Holmøy et al. JOURNAL OF NEUROLOGY
- Unraveling B lymphocytes in CNS inflammatory diseases
- (2020) Bruna Klein da Costa et al. NEUROLOGY
- A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders
- (2020) QinFang Xie et al. Multiple Sclerosis and Related Disorders
- Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment
- (2020) Sidney M. Gospe et al. EYE
- New therapies for neuromyelitis optica spectrum disorder
- (2020) Michael Levy et al. LANCET NEUROLOGY
- Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
- (2020) Jacqueline Palace et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 therapies and pregnancy in neuroimmunologic disorders
- (2020) Tania Kümpfel et al. Neurology-Neuroimmunology & Neuroinflammation
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
- (2020) Asya Izraelit Wallach et al. NEUROLOGIC CLINICS
- Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
- (2020) Edgar Patricio Correa-Díaz et al. Multiple Sclerosis and Related Disorders
- Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders
- (2019) Weilin Song et al. INTERNATIONAL OPHTHALMOLOGY
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- (2019) Sean J. Pittock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower serum interleukin‐22 and interleukin‐35 levels are associated with disease status in neuromyelitis optica spectrum disorders
- (2019) Hong Yang et al. CNS Neuroscience & Therapeutics
- Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
- (2019) Frederike C. Oertel et al. Journal of Neuroinflammation
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis
- (2019) John J. Chen et al. CURRENT OPINION IN NEUROLOGY
- Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis
- (2019) Miao-Miao Hou et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease
- (2019) Jacqueline F Rosenthal et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study
- (2019) Ziyan Shi et al. JOURNAL OF NEUROLOGY
- Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica
- (2019) Richard K. Burt et al. NEUROLOGY
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- (2019) Takashi Yamamura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource‐Limited Settings: Outcomes in a Multiethnic Single‐Center Population
- (2019) Zhi Miin Ong et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis
- (2019) Wenjuan Huang et al. Multiple Sclerosis and Related Disorders
- The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population
- (2019) Hudong Liang et al. JOURNAL OF NEUROIMMUNOLOGY
- Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
- (2019) Amy Kunchok et al. Multiple Sclerosis and Related Disorders
- Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
- (2019) Itay Lotan et al. Multiple Sclerosis and Related Disorders
- Investigational drugs in development to prevent neuromyelitis optica relapses
- (2018) Friedemann Paul et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
- (2018) Philippe Cabre et al. JOURNAL OF NEUROLOGY
- Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study
- (2018) Frederike C Oertel et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder
- (2018) Yang Yang et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Physiological effects of modulating the interleukin-6 axis
- (2018) Georg Schett RHEUMATOLOGY
- Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus and chronic obstructive pulmonary disease
- (2018) Katie Streicher et al. Arthritis & Rheumatology
- Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis
- (2018) Ying Wang et al. Frontiers in Neurology
- Blockade of IL-6 signaling in neuromyelitis optica
- (2018) Manabu Araki NEUROCHEMISTRY INTERNATIONAL
- Resolution of inflammation in neuromyelitis optica spectrum disorders
- (2018) Xu Wang et al. Multiple Sclerosis and Related Disorders
- Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
- (2018) Yan Wu et al. Multiple Sclerosis and Related Disorders
- Expansion of IL-6 + Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients
- (2017) Priscila O. Barros et al. JOURNAL OF NEUROIMMUNOLOGY
- Incidence and prevalence of NMOSD in Australia and New Zealand
- (2017) Wajih Bukhari et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Neuromyelitis Spectrum Disorders
- (2017) Brian G. Weinshenker et al. MAYO CLINIC PROCEEDINGS
- Neuromyelitis Optica Spectrum Disorders
- (2017) Tetsuya Akaishi et al. NEUROIMAGING CLINICS OF NORTH AMERICA
- Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature
- (2017) Saharat Aungsumart et al. Multiple Sclerosis and Related Disorders
- Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study
- (2016) Ying Fu et al. CNS Neuroscience & Therapeutics
- Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder
- (2016) H. Chen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Th17 cells in neuromyelitis optica spectrum disorder: a review
- (2016) Jie Lin et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study
- (2016) Yan Xu et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD
- (2016) Yaping Yan et al. Science China-Life Sciences
- Neuromyelitis optica spectrum disorders: An update
- (2015) Lekha Pandit Annals of Indian Academy of Neurology
- Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase
- (2015) P. O. Barros et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Rituximab does not reset defective early B cell tolerance checkpoints
- (2015) Nicolas Chamberlain et al. JOURNAL OF CLINICAL INVESTIGATION
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
- (2015) Dean M. Wingerchuk et al. NEUROLOGY
- Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
- (2015) Ingo Kleiter et al. Neurotherapeutics
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
- (2015) Su-Hyun Kim et al. JAMA Neurology
- Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
- (2014) Ramnath Santosh Ramanathan et al. BMC Neurology
- Neuromyelitis optica: clinical features, immunopathogenesis and treatment
- (2014) S. Jarius et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
- (2014) Liene Elsone et al. Multiple Sclerosis Journal
- Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder
- (2013) Hiroaki Yaguchi et al. INTERNAL MEDICINE
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
- (2013) Corinna Trebst et al. JOURNAL OF NEUROLOGY
- Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
- (2013) Sean J Pittock et al. LANCET NEUROLOGY
- Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica
- (2012) Takashi Kageyama et al. JOURNAL OF NEUROLOGY
- Aquaporin 4 and neuromyelitis optica
- (2012) Marios C Papadopoulos et al. LANCET NEUROLOGY
- Treatment of a Mouse Model of Spinal Cord Injury by Transplantation of Human Induced Pluripotent Stem Cell-Derived Long-Term Self-Renewing Neuroepithelial-Like Stem Cells
- (2012) Yusuke Fujimoto et al. STEM CELLS
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
- (2011) Norio Chihara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury
- (2010) Wolfram Tetzlaff et al. JOURNAL OF NEUROTRAUMA
- A Preliminary Result of Treatment of Neuromyelitis Optica With Autologous Peripheral Hematopoietic Stem Cell Transplantation
- (2010) Fuhua Peng et al. NEUROLOGIST
- B cells and multiple sclerosis
- (2008) Diego Franciotta et al. LANCET NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search